Stock Events

Stock Events

Lantern Pharma 

$2.34
33
+$0.05+2.18% Friday 20:00
+$0.04+1.71%Friday 22:15After hours

Statistics

Day High
2.37
Day Low
2.3
52W High
4.7
52W Low
1.11
Volume
3,319
Avg. Volume
-
Mkt Cap
29.91M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.57
-0.48
-0.39
-0.3
Expected EPS
-0.35
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-17.12MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LTRN. It's not an investment recommendation.
NVIDIA
9
NVDA
SoundHound AI
8
SOUN
Microsoft
6
MSFT
Alphabet
6
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences is a biopharmaceutical company that competes in the oncology space, similar to Lantern Pharma's focus on cancer treatment development.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. is a global healthcare company that develops cancer therapies, directly competing with Lantern Pharma's cancer-focused pipeline.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol-Myers Squibb operates in the biopharmaceutical industry, focusing on cancer drugs, which competes with Lantern Pharma's research and development in oncology.
Pfizer
PFE
Mkt Cap152.69B
Pfizer Inc. is involved in the discovery, development, and manufacture of healthcare products including oncology, competing with Lantern Pharma's cancer treatment innovations.
AMGEN
AMGN
Mkt Cap224.63B
Amgen Inc. focuses on human therapeutics, including oncology, which competes with Lantern Pharma's efforts in cancer drug development.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie Inc. engages in the discovery, development, manufacture, and sale of a broad line of pharmaceuticals, including in oncology, competing with Lantern Pharma.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops oncology treatments, competing with Lantern Pharma's cancer-focused therapies.
Novartis
NVS
Mkt Cap286.78B
Novartis AG focuses on the development of drugs in various therapeutic areas including oncology, directly competing with Lantern Pharma's cancer research efforts.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca PLC is a biopharmaceutical company focusing on the discovery and development of cancer treatments, competing with Lantern Pharma's oncology focus.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses worldwide, with a strong focus on oncology, competing with Lantern Pharma's cancer drug development.

About

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
Show more...
CEO
Panna Sharma
Employees
16
Country
United States
ISIN
US51654W1018

Listings

XNAS
US
LTRN
BOATS
BOATS
LTRN.BOATS

0 Comments

Share your thoughts

FAQ

What is Lantern Pharma stock price today?▼
The current price of LTRN is $2.34 USD — it has increased by +2.18% in the past 24 hours. Watch Lantern Pharma stock price performance more closely on the chart.
What is Lantern Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Lantern Pharma stocks are traded under the ticker LTRN.
Is Lantern Pharma stock price growing?▼
LTRN stock has fallen by -11.7% compared to the previous week, the month change is a -18.47% fall, over the last year Lantern Pharma has showed a -48.12% decrease.
What is Lantern Pharma market cap?▼
Today Lantern Pharma has the market capitalization of 29.91M
When is the next Lantern Pharma earnings date?▼
Lantern Pharma is going to release the next earnings report on November 11, 2026.
What were Lantern Pharma earnings last quarter?▼
LTRN earnings for the last quarter are -0.57 USD per share, whereas the estimation was -0.38 USD resulting in a -50% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Lantern Pharma revenue for the last year?▼
Lantern Pharma revenue for the last year amounts to 0 USD.
What is Lantern Pharma net income for the last year?▼
LTRN net income for the last year is -17.12M USD.
How many employees does Lantern Pharma have?▼
As of August 23, 2026, the company has 16 employees.
In which sector is Lantern Pharma located?▼
Lantern Pharma operates in the Health & Wellness sector.
When did Lantern Pharma complete a stock split?▼
Lantern Pharma has not had any recent stock splits.
Where is Lantern Pharma headquartered?▼
Lantern Pharma is headquartered in DALLAS, United States.